Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia

British Journal of Haematology

Volumn 134, Issue 2, 2006, Pages 184-186

  Cervantes, Francisco ^a,e   Alvarez Larrán, Alberto ^b   Hernández Boluda, Juan Carlos ^c   Sureda, Anna ^d   Granell, Miquel ^a   Vallansot, Rolando ^a   Besses, Carles ^b   Montserrat, Emili ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL DEL MAR   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

Author keywords

Anaemia; Darbepoetin alpha; Erythropoietin; Idiopathic myelofibrosis; Myelofibrosis with myeloid metaplasia; Treatment

Indexed keywords

ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN;

ADULT; AGE; AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HUMAN; MALE; MYELOFIBROSIS; MYELOID METAPLASIA; PRIORITY JOURNAL; TREATMENT RESPONSE; UNIVARIATE ANALYSIS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANEMIA; ERYTHROPOIETIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYELOFIBROSIS; MYELOID METAPLASIA; TREATMENT OUTCOME;

EID: 33745149293     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06142.x     Document Type: Article

References (12)

1. Barosi G. Ambrosetti A. Finelli G. Grossi A. Leoni P. Liberato NL. Petti MC. Pogliani E. Ricetti M. Rupoli S. Visani G. Tura S. ( 1999) The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia. British Journal of Haematology, 104, 730 737.
2. Barosi G. Bordessoule D. Brière J. Cervantes F. Demory JL. Dupriez B. Gisslinger H. Griesshammer M. Hasselbalch H. Kusec R. Le Bousse-Kerdilès MC. Liberato L. Marchetti M. Reilly JT. Thiele J. ( 2005) Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European myelofibrosis network (EUMNET). Blood, 106, 2849 2853.
3. Cervantes F. ( 2005) Modern management of myelofibrosis. British Journal of Haematology, 128, 583 592.
4. Cervantes F. Alvarez-Larrán A. Hernández-Boluda JC. Sureda A. Torrebadell M. Montserrat E. ( 2004) Erythropoietin treatment of the anaemia of myelofibrosis with myeloid metaplasia: results in 20 patients and review of the literature. British Journal of Haematology, 127, 399 403.
5. Cervantes F. Alvarez-Larrán A. Domingo A. Arellano-Rodrigo E. Montserrat E. ( 2005) Efficacy and tolerability of danazol as a treatment for the anaemia of myelofibrosis with myeloid metaplasia: long-term results in 30 patients. British Journal of Haematology, 129, 771 775.
6. Egrie JC. Brown JK. ( 2001) Development and characterization of novel erythropoiesis stimulating protein (NESP). British Journal of Cancer, 84 ( Suppl. 1 3 10.
7. Mesa RA. Tefferi A. ( 2001) Palliative splenectomy in myelofibrosis with myeloid metaplasia. Leukemia and Lymphoma, 42, 901 911.
8. Musto P. Lanza F. Balleari E. Grossi A. Falcone A. Sanpaulo G. Bodenizza C. Scalzulli PR. La Sala A. Camioni D. Ghio R. Cascavilla N. Carella AM. ( 2005) Darbepoetin alpha for the treatment of anaemia in low-intermediate risk myelodysplastic syndromes. British Journal of Haematology, 128, 204 209.
9. Nguyen VA. Fauser AA. Basara N. Kiehl M. ( 2003) Erythropoietic recovery during treatment with darbepoetin-alpha after impaired rHuEPO response to anemia in two patients with osteomyelofibrosis after peripheral blood stem cell transplantation. Hematology Journal, 4, 456 458.
10. Pirker R. ( 2004) Darbepoetin alfa for the treatment of cancer-related anemia: an update. Expert Review on Anticancer Therapy, 4, 735 744.
11. Toto R.D. Pichette V. Navarro J. Brenner R. Carroll W. Liu W. Roger S. ( 2004) Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. American Journal of Nephrology, 24, 453 460.
12. Waltzman RJ. ( 2004) Treatment of chemotherapy-related anemia with erythropoietic agents: current approaches and new paradigms. Seminars in Hematology, 41, 9 16.